Table 1. Characteristics of the studies eligible for meta-analysis.
First author | Year | Country | Ethnicity | Type of cancer | Source of control | Genotyping method | Case/control | Cases | Controls | HWE | Score | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gly388Arg rs351855 G>A | GG | AG | AA | G | A | GG | AG | AA | G | A | |||||||||
Ansell | 2009 | Sweden | Caucasian | HNSCC | PB | PCR-RFLP | 110/192 | 61 | 49 | - | - | 81 | 111 | - | - | - | 9 | ||
Bange | 2002 | Russia | Caucasian | Breast | PB | PCR-RFLP | 61/123 | 26 | 28 | 7 | 80 | 42 | 55 | 60 | 8 | 170 | 76 | 0.114 | 7 |
Bange | 2002 | Germany | Caucasian | Breast | PB | PCR-RFLP | 84/123 | 41 | 34 | 9 | 116 | 52 | 55 | 60 | 8 | 170 | 76 | 0.114 | 8 |
Bange | 2002 | Italy | Caucasian | Colon cancer | PB | PCR-RFLP | 82/123 | 37 | 38 | 7 | 112 | 52 | 55 | 60 | 8 | 170 | 76 | 0.114 | 8 |
Batschauer | 2011 | Brazil | Caucasian | Breast | PB | PCR-RFLP | 68/85 | 39 | 26 | 3 | 104 | 32 | 47 | 35 | 3 | 129 | 41 | 0.249 | 9 |
Chen | 2018 | Taiwan | Asian | Cervical cancer | HB | TaqMan | 226/335 | 69 | 101 | 56 | 239 | 213 | 96 | 165 | 74 | 357 | 313 | 0.845 | 9 |
Chou | 2017 | Taiwan | Asian | OSCC | PB | TaqMan | 955/1191 | 225 | 524 | 206 | 974 | 936 | 334 | 596 | 261 | 1264 | 1118 | 0.873 | 11 |
Fang | 2013 | China | Asian | NSCLC | HB | Sequencing | 629/729 | 193 | 331 | 105 | 717 | 541 | 163 | 391 | 175 | 717 | 741 | 0.049 | 9 |
FitzGerald | 2009 | U.S.A. | Caucasian | Prostate | PB | SNPlex | 1254/1251 | 587 | 544 | 123 | 1718 | 790 | 631 | 496 | 124 | 1758 | 744 | 0.070 | 15 |
FitzGerald | 2009 | U.S.A. | African | Prostate | PB | SNPlex | 146/80 | 104 | 39 | 3 | 247 | 45 | 60 | 18 | 2 | 138 | 22 | 0.646 | 13 |
Gao | 2014 | China | Asian | NHL | NA | PCR-RFLP | 421/486 | 117 | 189 | 115 | 423 | 419 | 171 | 240 | 75 | 582 | 390 | 0.541 | 11 |
Heinzle | 2012 | Austria | Caucasian | Colon cancer | PB | TaqMan | 85/1660 | 42 | 33 | 10 | 117 | 53 | 802 | 723 | 135 | 2327 | 993 | 0.114 | 10 |
Ho | 2009 | Singapore | Asian | HCC | PB | Sequencing | 58/88 | 27 | 17 | 14 | 71 | 45 | 30 | 38 | 20 | 98 | 78 | 0.241 | 6 |
Ho | 2010 | U.K. | Caucasian | Prostate | PB | TaqMan | 397/291 | 183 | 182 | 32 | 548 | 246 | 150 | 117 | 24 | 417 | 165 | 0.860 | 11 |
Hosseini | 2017 | Iran | Asian | Breast Cancer | PB | PCR-RFLP | 126/160 | 87 | 33 | 6 | 207 | 45 | 54 | 57 | 49 | 165 | 155 | <0.001 | 6 |
Jiang | 2015 | China | Asian | Breast cancer | NA | Snapshot | 747/716 | 205 | 404 | 138 | 814 | 680 | 270 | 348 | 98 | 888 | 544 | 0.398 | 12 |
Li | 2017 | China | Asian | Cervical Cancer | HB | PCR-RFLP | 162/162 | 35 | 79 | 48 | 149 | 175 | 50 | 72 | 40 | 172 | 152 | 0.170 | 8 |
Ma | 2008 | Japan | Asian | Prostate | HB | PCR-RFLP | 492/179 | 163 | 196 | 133 | 522 | 462 | 67 | 87 | 25 | 221 | 137 | 0.701 | 10 |
Mawrin | 2006 | Germany | Caucasian | Glioma | HB | PCR-RFLP | 94/25 | 39 | 51 | 4 | 129 | 59 | 10 | 13 | 2 | 33 | 17 | 0.428 | 6 |
Morimoto | 2003 | Japan | Asian | Sarcomas | NA | PCR-RFLP | 143/102 | 54 | 72 | 17 | 180 | 106 | 39 | 50 | 13 | 128 | 76 | 0.624 | 10 |
Naidu | 2009 | Malaysia | Asian | Breast | HB | PCR-RFLP | 387/252 | 179 | 172 | 36 | 530 | 244 | 132 | 105 | 15 | 369 | 135 | 0.322 | 9 |
Nan | 2009 | U.S.A. | Caucasian | Skin cancer | PB | TaqMan | 768/833 | 365 | 325 | 78 | 1055 | 481 | 406 | 343 | 84 | 1155 | 511 | 0.359 | 11 |
Shen | 2013 | China | Asian | Gastric cancer | PB | Sequencing | 304/392 | 118 | 124 | 62 | 360 | 248 | 132 | 188 | 72 | 452 | 332 | 0.724 | 11 |
Sheu | 2015 | China | Asian | HCC | HB | TaqMan | 289/595 | 82 | 150 | 57 | 314 | 264 | 159 | 314 | 122 | 632 | 558 | 0.146 | 8 |
Spinola | 2005 | Italy | Caucasian | Lung | HB | Pyrosequencing | 274/401 | 148 | 104 | 22 | 400 | 148 | 193 | 168 | 40 | 554 | 248 | 0.699 | 9 |
Spinola | 2005 | Italy | Caucasian | Breast | HB | Pyrosequencing | 142/220 | 67 | 55 | 20 | 189 | 95 | 112 | 83 | 25 | 307 | 133 | 0.117 | 8 |
Spinola | 2005 | Italy | Caucasian | CRC | HB | Pyrosequencing | 179/220 | 98 | 63 | 18 | 259 | 99 | 112 | 83 | 25 | 307 | 133 | 0.117 | 8 |
Tanuma | 2010 | Japan | Asian | OSCC | HB | PCR-SSCP | 150/100 | 69 | 53 | 28 | 191 | 109 | 42 | 48 | 10 | 132 | 68 | 0.487 | 8 |
Tsay | 2020 | Taiwan | Asian | Cervical cancer | HB | TaqMan | 428/856 | 114 | 222 | 92 | 450 | 406 | 242 | 426 | 188 | 910 | 802 | 0.984 | 10 |
Ture | 2015 | Turkey | Asian | Lung cancer | HB | PCR-RFLP | 124/100 | 66 | 47 | 11 | 179 | 69 | 48 | 46 | 6 | 142 | 58 | 0.242 | 7 |
Wang | 2004 | U.S.A. | Caucasian | Prostate | PB | PCR-RFLP | 284/97 | 125 | 117 | 42 | 367 | 201 | 53 | 40 | 4 | 146 | 48 | 0.291 | 8 |
Wang | 2004 | U.S.A. | African | Prostate | PB | PCR-RFLP | 45/94 | 37 | 6 | 2 | 80 | 10 | 76 | 18 | 0 | 170 | 18 | 0.305 | 7 |
Whittle | 2016 | U.S.A. | Caucasian | Neuroblastoma | NA | PCR-RFLP | 126/114 | 45 | 69 | 12 | 159 | 93 | 50 | 60 | 4 | 160 | 68 | 0.006 | 9 |
Wimmer | 2019 | Germany | Caucasian | HNSCC | PB | PCR-RFLP | 284/123 | 188 | 84 | 12 | 460 | 108 | 55 | 60 | 8 | 170 | 76 | 0.114 | 9 |
Yang | 2012 | China | Asian | HCC | HB | TaqMan | 711/740 | 216 | 351 | 144 | 783 | 639 | 247 | 361 | 132 | 855 | 625 | 0.996 | 10 |
First author | Year | Country | Ethnicity | Type of Cancer | Source of control | Genotyping method | Case/control | Cases | Controls | HWE | Score | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Val10Ile rs1966265 | CC | CT | TT | C | T | CC | CT | TT | C | T | |||||||||
Chen | 2018 | Taiwan | Asian | Uterine Cervical | HB | TaqMan | 227/335 | 61 | 105 | 61 | 227 | 227 | 91 | 168 | 76 | 350 | 320 | 0.927 | 9 |
Chou | 2017 | Taiwan | Asian | OSCC | PB | TaqMan | 955/1191 | 213 | 514 | 228 | 940 | 970 | 285 | 580 | 326 | 1150 | 1232 | 0.391 | 11 |
FitzGerald | 2009 | U.S.A. | Caucasian | Prostate | PB | SNPlex | 1259/1254 | 782 | 405 | 72 | 1969 | 549 | 742 | 447 | 65 | 1931 | 577 | 0.827 | 15 |
FitzGerald | 2009 | U.S.A. | African | Prostate | PB | SNPlex | 147/80 | 132 | 15 | 0 | 279 | 15 | 70 | 10 | 0 | 150 | 10 | 0.551 | 13 |
Jiang | 2015 | China | Asian | Breast | NA | Snapshot | 747/716 | 171 | 408 | 168 | 750 | 744 | 126 | 364 | 226 | 616 | 816 | 0.322 | 12 |
Nan | 2009 | U.S.A. | Caucasian | Skin cancer | PB | TaqMan | 753/821 | 461 | 251 | 41 | 1173 | 333 | 507 | 271 | 43 | 1285 | 357 | 0.390 | 11 |
Sheu | 2015 | China | Asian | HCC | HB | TaqMan | 289/595 | 65 | 160 | 64 | 290 | 288 | 151 | 300 | 144 | 602 | 588 | 0.835 | 8 |
Tsay | 2020 | Taiwan | Asian | Cervical cancer | HB | TaqMan | 428/856 | 95 | 226 | 107 | 416 | 440 | 215 | 420 | 221 | 850 | 862 | 0.585 | 10 |
First author | Year | Country | Ethnicity | Type of cancer | Source of control | Genotyping method | Case/control | Cases | Controls | HWE | Score | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
rs7708357 | GG | GA | AA | G | A | GG | GA | AA | G | A | |||||||||
Chen | 2018 | Taiwan | Asian | Uterine cervical | HB | TaqMan | 227/335 | 222 | 4 | 1 | 448 | 6 | 321 | 13 | 1 | 655 | 15 | 0.038 | 9 |
Chou | 2017 | Taiwan | Asian | OSCC | PB | TaqMan | 955/1191 | 932 | 22 | 1 | 1886 | 24 | 1167 | 23 | 1 | 2357 | 25 | 0.015 | 11 |
FitzGerald | 2009 | U.S.A. | Caucasian | Prostate | PB | SNPlex | 1258/1254 | 459 | 632 | 167 | 1550 | 966 | 507 | 569 | 178 | 1583 | 925 | 0.368 | 15 |
FitzGerald | 2009 | U.S.A. | African | Prostate | PB | SNPlex | 146/78 | 49 | 74 | 23 | 172 | 120 | 34 | 35 | 9 | 103 | 53 | 0.999 | 13 |
Sheu | 2015 | China | Asian | HCC | HB | TaqMan | 289/595 | 283 | 5 | 1 | 571 | 7 | 577 | 18 | 0 | 1172 | 18 | 0.708 | 8 |
Tsay | 2020 | Taiwan | Asian | Cervical cancer | HB | TaqMan | 428/856 | 416 | 10 | 2 | 842 | 14 | 838 | 17 | 1 | 1693 | 19 | 0.005 | 9 |
First author | Year | Country | Ethnicity | Type of cancer | Source of control | Genotyping method | Case/control | Cases | Controls | HWE | Score | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
rs2011077 | CC | CT | TT | C | T | CC | CT | TT | C | T | |||||||||
Chen | 2018 | Taiwan | Asian | UT-cervical | HB | TaqMan | 227/335 | 63 | 102 | 62 | 228 | 226 | 94 | 163 | 78 | 351 | 319 | 0.652 | 9 |
Chou | 2017 | Taiwan | Asian | OSCC | PB | TaqMan | 955/1191 | 210 | 509 | 236 | 929 | 981 | 288 | 577 | 326 | 1153 | 1229 | 0.299 | 11 |
Ma | 2008 | Japan | Asian | Prostate | HB | PCR-RFLP | 492/179 | 94 | 285 | 113 | 473 | 511 | 11 | 85 | 83 | 107 | 251 | 0.075 | 10 |
Sheu | 2015 | China | Asian | HCC | HB | TaqMan | 289/595 | 66 | 159 | 64 | 291 | 287 | 147 | 297 | 151 | 591 | 599 | 0.968 | 8 |
Tsay | 2020 | Taiwan | Asian | Cervical cancer | HB | TaqMan | 428/856 | 94 | 224 | 110 | 412 | 444 | 217 | 418 | 221 | 852 | 860 | 0.495 | 10 |
First author | Year | Country | Ethnicity | Type of cancer | Source of control | Genotyping method | Case/control | Cases | Controls | HWE | Score | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
rs376618 | AA | AG | GG | A | G | AA | AG | GG | A | G | |||||||||
FitzGerald | 2009 | U.S.A. | Caucasian | Prostate | PB | SNPlex | 1238/1245 | 703 | 448 | 87 | 1854 | 622 | 712 | 437 | 96 | 1861 | 629 | 0.013 | 15 |
FitzGerald | 2009 | U.S.A. | African | Prostate | PB | SNPlex | 145/80 | 65 | 59 | 21 | 189 | 101 | 38 | 38 | 4 | 114 | 46 | 0.154 | 13 |
Nan | 2009 | U.S.A. | Caucasian | Skin cancer | PB | TaqMan | 762/830 | 451 | 273 | 38 | 1175 | 349 | 468 | 326 | 36 | 1262 | 398 | 0.026 | 11 |